Mesoblast Provides Half Year Results and Corporate Update
Filed with ASX · · 9 pages · English
In the deck
Story so far
Earlier from Mesoblast
- Mesoblast Submits Completed BLA for Ryoncil to US FDA
- Appendix 4C - quarterly
- MSB Files GvHD Clinical Efficacy and Safety Data with US FDA
- DMC Completes Final Review of Phase 3 Heart Failure Trial
- CHF P3Trial Accrues Sufficient Primary EndPt Events(Correct)
Later from Mesoblast
- Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease
- FDA Accepts BLA for RYONCIL and Agrees to Priority Review
- FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients
- US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial
- 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast